Jump to content
Sclero Forums

Search the Community

Showing results for tags 'endocannabinoid system'.



More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • Worldwide
    • Welcome: Guidelines and FAQs
    • Sclero Forums (MAIN)
    • UK Scleroderma
    • News
    • Personal Support

Blogs

  • CFM Babs from Chorley FM
  • barefut impressions
  • My Two Cents...
  • Amanda Thorpe's Blog
  • Joelf's Blog
  • Michael Thorpe's Blog

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Joined

  • Start

    End


Group


Location

Found 12 results

  1. Potential Cannabidiol Treatment EHP-101 Shows Safety in Early Trial, Study in Scleroderma Patients Being Readied. EHP-101, an oral cannabidiol treatment candidate for people with scleroderma (SSc) and multiple sclerosis (MS), was found to be safe and well-tolerated in a Phase 1 clinical trial in healthy volunteers. Scleroderma News, 08/28/2019. (Also see Endocannabinoid System) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  2. Arthritis group offers first guidelines for patients who use cannabidiol (CBD) for joint pain. The Arthritis Foundation released guidelines for people who want to try CBD — the first such guidance on using the cannabis-derived ingredient from any major patient advocacy group. NBC Health News, 09/24/2019. (Also see Endocannabinoid System) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  3. Can CBD Really Do All That? How one molecule from the cannabis plant came to be seen as a therapeutic cure–all. New York Times, 05/14/2019. (Also see Endocannabinoid System) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  4. Regular marijuana users may need more anesthesia for medical procedures. Patients getting surgery may need higher levels of anesthesia if they are regular marijuana users, a new study suggests. NBC Health News, 04/16/2019. (Also see Endocannabinoid System) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  5. Cannabinoid derivatives acting as dual PPARγ/CB2 agonists as therapeutic agents for systemic sclerosis (SSc). Altogether the results indicate that dual PPARγ/CB2 agonists qualify as a novel therapeutic approach for the treatment of SSc and other fibrotic diseases. PubMed, Biochem Pharmacol, 2019 Feb 27;163:321-334. (Also see Endocannabinoid System) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  6. Cannabinoid Signaling in the Skin: Therapeutic Potential of the "C(ut)annabinoid" System. The current review aims to give an overview of the available skin–relevant endo– and phytocannabinoid literature with a special emphasis on the putative translational potential. PubMed, Molecules, 2019 Mar 6;24(5). (Also see Endocannabinoid System) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles. 
  7. Corbus Pharmaceuticals Expands Target Indications by Adding More Than 600 Compounds Focused on the Endocannabinoid System from Jenrin Discovery. Corbus Pharmaceuticals Holdings, Inc. announced today that it has licensed the exclusive worldwide rights to develop, manufacture and market drug candidates, which includes CRB-4001, a peripherally–restricted, CB1 inverse agonist targeting liver, lung, heart and kidney fibrotic diseases. Corbus Pharmaceuticals, 09/20/2018. (Also see Clinical Trials and Endocannabinoid System) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  8. Corbus Pharmaceuticals to Commence Phase 3 Study of Lenabasum for the Treatment of Rare Autoimmune Disease Dermatomyositis. Corbus Pharmaceuticals announced today that the Company will proceed with a Phase 3 trial evaluating the efficacy and safety of lenabasum for the treatment of dermatomyositis. Globe Newswire, 07/25/2018. (Also see Treatments for Dermatomyositis, Endocannabinoid System and Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  9. The relationship of endocannabinoidome lipid mediators with pain and psychological stress in women with fibromyalgia (FM)– a case control study. This study reports about elevated plasma levels of endocannabinoidome lipid mediators in FM. PubMed, J Pain, 06/06/2018. (Also see Endocannabinoid System and Treatments for Fibromyalgia) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  10. Intestinal microbiome in scleroderma (SSc): recent progress. Emerging evidence suggests that alterations in gut microbiota exist in the SSc disease state and more studies are needed to ascertain the mechanism by which these alterations perpetuate inflammation and fibrosis in SSc. PubMed, Curr Opin Rheumatol, 2017 Nov;29(6):553-560. (Also see Bowel Dysfunction and Endocannabinoid System) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  11. Corbus Wins Expanded U.S. Patent Coverage of Anabasum Therapy for Systemic Sclerosis. Corbus Pharmaceuticals has extended its intellectual property portfolio with a new patent for its investigative cannabinoid–derived drug candidate anabasum to treat inflammatory diseases. Scleroderma News, 11/02/2017. (Also see Clinical Trials and Endocannabinoid System) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  12. Endocannabinoid System (ECS) The Endocannabinoid System is the name for a series of endogenous cell receptors that respond to certain kinds of agonists, located in the mammalian brain and throughout the central and peripheral nervous systems. Posted 10/17/2017. This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
×
×
  • Create New...